Co-Diagnostics, Inc. to Present at Utah Mosquito Abatement Association Conference

Date : 10/29/2018 @ 10:30AM
Source : Business Wire
Stock : Co Diagnostics Inc (CODX)
Quote : 1.0  0.015 (1.52%) @ 4:59AM
Co Diagnostics share price Chart
After Hours
Last Trade
Last $ 0.99 ▼ -0.01 (-1.00%)

Co-Diagnostics, Inc. to Present at Utah Mosquito Abatement Association Conference

Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart

2 Years : From Dec 2017 to Dec 2019

Click Here for more Co Diagnostics Charts.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it will be offering a presentation of its mosquito vector control program at the 71st Annual Utah Mosquito Abatement Association conference in Ogden, Utah on October 29, 2018.

From the website of the Utah Mosquito Abatement Association (UMAA), the UMAA was founded in 1948, with the goal of promoting close cooperation among those concerned with, or interested in mosquito control and related work, to increase the knowledge and advance the cause of mosquito abatement in an efficient and effective manner compatible with the goals of a sound environment.

Vector is the term used to describe an organism that transmits infectious disease across human or animal populations. Co-Diagnostics’ vector control program will involve technology provided by the Company for use in vector control services to test mosquito populations where the insect is known or suspected to act as a vector. The UMAA conference will include a brief presentation of the technology used by the Company in vector control programs, as well as meetings with several department heads and directors of organizations across the state involved with control and abatement of mosquitos carrying diseases like West Nile virus.

Co-Diagnostics CEO Dwight Egan commented, “We believe Co-Diagnostics is an ideal partner to provide support in pairing disease detection with vector control programs. Our proprietary design platform allows us to provide products that meet this demand via patented, state-of-the-art technology that represents a leap forward in the understanding of real-time PCR molecular diagnostics. Tests used in vector control programs are not intended to diagnose humans, and are therefore subject to different regulatory requirements. This will allow our products to be manufactured locally in the Company’s ISO 13485:2016 facility, and sold throughout the United States without 510(k) clearance or Premarket Authorization (“PMA”) from the FDA.

“The opportunity to provide vector control tests extends throughout vast regions of the world that are home to more than 2 billion people who are vulnerable to serious infections from mosquitoes. Co-Diagnostics has many tests completed or in development with direct vector control applications, including those for Zika, tuberculosis, malaria, and Zika/dengue/chikungunya multiplex, among others.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with a proprietary diagnostic testing technology and development platform that intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and license the use of its platform to other non-competing developers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Company Contact:Co-Diagnostics, Inc.Andrew BensonCo-Diagnostics Investor Relations801-438-1036investors@codiagnostics.comorInvestor Contact:Lytham Partners, LLCJoe Diaz, Robert Blum and Joe

Latest CODX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191215 08:48:35